TG2-179-1
TG2-179-1 is a potent BAP1 inhibitor. TG2-179-1 inhibits the domain-containing deubiquitinase (DUB) activity of BAP1 by covalently binding to its active site. TG2-179-1 exerts cytotoxic activity, leading to defective replication and increased apoptosis. TG2-179-1 has the potential for colon cancer research[1].
Product Specifications
CAS Number
1135023-19-6
UNSPSC
12352005
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tg2-179-1.html
Purity
99.67
Solubility
DMF : 2 mg/mL (ultrasonic; warming) |DMSO : 50 mg/mL (ultrasonic)
Smiles
N#CC1=C(NC(CSC2=NN=C(C3=CC=C(Cl)C=C3)O2)=O)SC(C)=C1C4=CC=C(C=C4)F
Molecular Formula
C22H14ClFN4O2S2
Molecular Weight
484.95
References & Citations
[1]Minhwa Kang, et al. Targeting BAP1 with small compound inhibitor for colon cancer treatment. Sci Rep. 2023 Feb 8;13 (1) :2264.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
NME1 / nm23-H1 / NDPK-A (Suppressor of Metastasis) (CPTC-NME1-2), CF594 conjugate, 0.1mg/mL
